To include your compound in the COVID-19 Resource Center, submit it here.

Omthera: Fishing expedition

Omthera's omega-3 fatty acid to take on Lovaza in lipid-lowering competition

Omthera Pharmaceuticals Inc. believes superior bioavailability and greater dosing flexibility will enable its Epanova omega-3 fatty acid to compete in the $1 billion market for lipid-lowering drugs now occupied by Lovaza.

Epanova is a mixture of the free fatty acid forms of the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which lower triglycerides by mechanisms that are not well understood.

According to CMO Michael Davidson, a "free fatty acid is already 'digested' so to speak, so it's more easily absorbed" than an ethyl ester fatty acid

Read the full 899 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE